|
NOTE
5:- OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES
| |
|
December 31, |
|
| |
|
2019 |
|
|
2018 |
|
| |
|
USD |
|
| |
|
|
|
|
|
|
| Government authorities |
|
$ |
14 |
|
|
$ |
41 |
|
| Asset related to Univo transaction (*) |
|
|
637 |
|
|
|
- |
|
| Prepaid expenses and others |
|
$ |
3,732 |
|
|
$ |
3,974 |
|
| |
|
|
|
|
|
|
|
|
| |
|
$ |
4,383 |
|
|
$ |
4,015 |
|
| (*) |
On September 10, 2019, the Company entered into a collaboration agreement
with Univo, a medical cannabis company, to identify and co-develop specific formulations of cannabis components for the treatment
of cancer, inflammatory, autoimmune, and metabolic diseases.. Under this collaboration agreement, Univo will provide the Company
with cannabis and cannabis components, as well as full access to its laboratories for both research and manufacturing. The Company
agreed to pay Univo a total of USD 500 in two instalments and issued to Univo 19,934,355 of its ordinary shares through a private
placement, representing approximately 16.6% of the Company's ordinary shares outstanding after giving effect to the issuance.
The companies will initially share ownership of intellectual property developed in this collaboration. Revenues derived from the
collaboration will generally be shared between the Company and Univo on the basis of each party's contribution. See also
Note 7. |
|